UC
MCID: ULC004
MIFTS: 76

Ulcerative Colitis (UC) malady

Categories: Gastrointestinal diseases

Aliases & Classifications for Ulcerative Colitis

Aliases & Descriptions for Ulcerative Colitis:

Name: Ulcerative Colitis 38 12 25 41 3 14 69
Inflammatory Bowel Disease, Ulcerative Colitis Type 25
Chronic Left-Sided Ulcerative Colitis 69
Left-Sided Ulcerative Colitis 12
Left Sided Ulcerative Colitis 69
Idiopathic Proctocolitis 25
Colitis, Ulcerative 42
Colitis Ulcerative 52
Colitis Gravis 25
Uc 25

Classifications:



Summaries for Ulcerative Colitis

MedlinePlus : 41 ulcerative colitis (uc) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. it is one of a group of diseases called inflammatory bowel disease. uc can happen at any age, but it usually starts between the ages of 15 and 30. it tends to run in families. the most common symptoms are pain in the abdomen and blood or pus in diarrhea. other symptoms may include anemia severe tiredness weight loss loss of appetite bleeding from the rectum sores on the skin joint pain growth failure in children about half of people with uc have mild symptoms. doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose uc. several types of drugs can help control it. some people have long periods of remission, when they are free of symptoms. in severe cases, doctors must remove the colon. nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Ulcerative Colitis, also known as inflammatory bowel disease, ulcerative colitis type, is related to pyoderma gangrenosum and colorectal cancer, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Ulcerative Colitis is MUC2 (Mucin 2, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Infliximab and Sucralfate have been mentioned in the context of this disorder. Affiliated tissues include Bone, colon and testes, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Genetics Home Reference : 25 Ulcerative colitis is a chronic disorder that affects the digestive system. This condition is characterized by abnormal inflammation of the inner surface of the rectum and colon, which make up most of the length of the large intestine. The inflammation usually causes open sores (ulcers) to develop in the large intestine. Ulcerative colitis usually appears between ages 15 and 30, although it can develop at any age. The inflammation tends to flare up multiple times throughout life, which causes recurring signs and symptoms.

Disease Ontology : 12 A colitis that is predominantly confined to the mucosa located in colon and includes characteristic ulcers, or open sores.

Wikipedia : 71 Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon... more...

Related Diseases for Ulcerative Colitis

Diseases related to Ulcerative Colitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 637)
id Related Disease Score Top Affiliating Genes
1 pyoderma gangrenosum 32.2 CXCL8 IFNG IL1B IL6 TNF
2 colorectal cancer 31.8 CXCL8 IFNG IL10 IL1B IL2 IL6
3 hepatitis 30.6 IFNG IL10 IL2 IL6 TNF
4 pericholangitis 30.4 CRP MPO MUC2 TLR4 TNF
5 crohn's colitis 30.4 IL6 MPO NOD2 TLR4 TNF
6 celiac disease 30.2 CRP NOD2 TNF
7 tuberculosis 30.1 IL10 IL1B IL2 IL6 TNF
8 rosacea 30.0 IFNG IL10 IL1B
9 histiocytoma 29.8 CXCL8 NOD2 TNF
10 hidradenitis 29.7 CRP CXCL8 IL1B
11 labyrinthitis 29.6 CXCL8 IL10 IL1B IL6 TNF
12 neuropathy 29.6 CRP CXCL8 IL1B IL6 TLR4 TNF
13 rheumatoid arthritis 29.6 CRP CXCL8 IFNG IL10 IL1B IL2
14 osteonecrosis 29.5 CRP CXCL8 IL1B IL6 TNF
15 membranoproliferative glomerulonephritis 29.4 CRP IL10 IL2 IL6 MUC2 TNF
16 granulomatous hepatitis 29.4 CRP IL1B IL6
17 colon adenocarcinoma 29.4 CRP CXCL8 IL10 IL1B IL6 TNF
18 histiocytosis 29.4 CRP CXCL8 IL1B IL6 TLR4 TNF
19 collagenous colitis 29.0 CLDN18 CRP CXCL8 IFNG IL10 IL1B
20 pediatric ulcerative colitis 12.2
21 inflammatory bowel disease 1 11.7
22 ulcerative proctitis 11.4
23 inflammatory bowel disease 11.4
24 pouchitis 11.3
25 bile duct carcinoma 11.2
26 colitis 11.2
27 colonic disease 11.2
28 inflammatory bowel disease 19 11.0
29 inflammatory bowel disease 17, protection against 11.0
30 inflammatory bowel disease 25, early onset, autosomal recessive 11.0
31 inflammatory bowel disease 13 11.0
32 inflammatory bowel disease 14 11.0
33 inflammatory bowel disease 10 11.0
34 inflammatory bowel disease 28, early onset, autosomal recessive 11.0
35 autoimmune disease 6 10.9
36 cholangitis, primary sclerosing 10.9
37 colorectal cancer 12 10.9
38 chemical colitis 10.9
39 colorectal cancer 3 10.9
40 colorectal cancer 10 10.9
41 colorectal cancer 1 10.9
42 fecal incontinence 10.9
43 myelodysplastic myeloproliferative cancer 10.8
44 crohn's disease 10.6
45 mucositis 10.5
46 cholangitis 10.4
47 sclerosing cholangitis 10.4
48 intussusception 10.4 IL1B TNF
49 pyridoxal 5'-phosphate-dependent epilepsy 10.4 IL10 TNF
50 steatitis 10.4 IL2 TNF

Comorbidity relations with Ulcerative Colitis via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Crohn's Disease Deficiency Anemia
Esophagitis Hypothyroidism
Inflammatory Bowel Disease 1 Intestinal Obstruction
Iron Deficiency Anemia Paralytic Ileus
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Ulcerative Colitis:



Diseases related to Ulcerative Colitis

Symptoms & Phenotypes for Ulcerative Colitis

UMLS symptoms related to Ulcerative Colitis:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas

GenomeRNAi Phenotypes related to Ulcerative Colitis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 MPO MYO9B NOD2 TNF CXCL8 IL10
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 MPO MYO9B NOD2 TNF CXCL8 IL10

MGI Mouse Phenotypes related to Ulcerative Colitis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.28 MUC2 MYO9B NOD2 REL TLR4 TNF
2 homeostasis/metabolism MP:0005376 10.27 CLDN18 CRP IFNG IL10 IL1B IL2
3 cardiovascular system MP:0005385 10.22 CRP IFNG IL10 IL1B IL2 IL6
4 cellular MP:0005384 10.2 CLDN18 IFNG IL10 IL2 IL6 MUC2
5 immune system MP:0005387 10.2 CLDN18 CRP IFNG IL10 IL1B IL2
6 digestive/alimentary MP:0005381 10.17 MUC2 NOD2 REL TLR4 TNF CLDN18
7 neoplasm MP:0002006 9.81 TLR4 TNF IFNG IL10 IL1B IL2
8 liver/biliary system MP:0005370 9.8 IFNG IL10 IL2 IL6 REL TLR4
9 respiratory system MP:0005388 9.56 CLDN18 IFNG IL10 IL2 IL6 REL
10 skeleton MP:0005390 9.28 TNF CLDN18 IFNG IL10 IL1B IL6

Drugs & Therapeutics for Ulcerative Colitis

Drugs for Ulcerative Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 306)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 4,Phase 2,Phase 3,Phase 1 170277-31-3
2
Sucralfate Approved Phase 4 54182-58-0
3
Azathioprine Approved Phase 4,Phase 2,Phase 3 446-86-6 2265
4
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
5
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 331731-18-1 16219006
6
Aminosalicylic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1 65-49-6 4649
7
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 73590-58-6 4594
8
Ciprofloxacin Approved, Investigational Phase 4,Phase 2 85721-33-1 2764
9
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2 79217-60-0, 59865-13-3 5284373 6435893
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
11
Benzocaine Approved Phase 4,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
12
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
13
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
14
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
15
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
16
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1 443-48-1 4173
17
Nicotine Approved Phase 4 54-11-5 942 89594
18
Vedolizumab Approved Phase 4,Phase 3,Phase 2 943609-66-3
19
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-23-7 5754 657311
20
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
21
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
22
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 1 93-14-1 3516
23
Vancomycin Approved Phase 4,Phase 1 1404-90-6 441141 14969
24
Methotrexate Approved Phase 4,Phase 2 1959-05-2, 59-05-2 126941
25
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
26
Losartan Approved Phase 4 114798-26-4 3961
27
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
28
Copper Approved Phase 4 15158-11-9, 7440-50-8 27099
29
Zinc Approved Phase 4 7440-66-6 32051 23994
30
Thioguanine Approved Phase 4 154-42-7 2723601
31
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
32 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 1
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
34
leucovorin Approved, Nutraceutical Phase 4,Phase 2 58-05-9 54575, 6560146 143
35
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
36
Caffeine Approved, Nutraceutical Phase 4 58-08-2 2519
37
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-02-9 14985
38
Butyric Acid Experimental Phase 4,Phase 2 107-92-6 264
39 Antibodies Phase 4,Phase 2,Phase 3,Phase 1
40 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3,Phase 1
41 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1
42 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Dermatologic Agents Phase 4,Phase 2,Phase 3,Phase 1
44 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1
45 Antacids Phase 4,Phase 2
46 Anti-Ulcer Agents Phase 4,Phase 2
47 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
49 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
50 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 820)
id Name Status NCT ID Phase
1 Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission Unknown status NCT02412085 Phase 4
2 Role of Healthy Bacteria in Ulcerative Colitis Unknown status NCT01479660 Phase 4
3 Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab Unknown status NCT02186886 Phase 4
4 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" Unknown status NCT02452151 Phase 4
5 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation Unknown status NCT01078935 Phase 4
6 Confocal Endomicroscopy During Endoscopy Unknown status NCT00988273 Phase 4
7 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4
8 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Unknown status NCT01632462 Phase 4
9 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4
10 ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial Unknown status NCT02016807 Phase 4
11 Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4
12 A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients Completed NCT00207688 Phase 4
13 Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis Completed NCT01408810 Phase 4
14 Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC) Completed NCT00446849 Phase 4
15 Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4
16 European Safety Registry in Ulcerative Colitis (Study P04808AM3) Completed NCT00705484 Phase 4
17 Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis Completed NCT01201122 Phase 4
18 Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) Completed NCT02092285 Phase 4
19 Asacol Dosing Study for Active Ulcerative Colitis Completed NCT00194818 Phase 4
20 Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) Completed NCT02155335 Phase 4
21 Adacolumn in Refractory UC Patients Trial Completed NCT01481142 Phase 4
22 Dose Escalation and Remission (DEAR) Completed NCT00652145 Phase 4
23 Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis Completed NCT01124149 Phase 4
24 Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205) Completed NCT00219414 Phase 4
25 Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4
26 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD) Completed NCT01346826 Phase 4
27 Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
28 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate Completed NCT01991314 Phase 4
29 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4
30 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4
31 Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients Completed NCT01341808 Phase 4
32 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4
33 Efficacy Study of Pneumococcal Vaccination in Crohn's Disease Completed NCT01505855 Phase 4
34 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4
35 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Completed NCT01034358 Phase 4
36 A Trial of Iron Replacement in Patients With Iron Deficiency. Completed NCT01067547 Phase 4
37 Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis Recruiting NCT02345733 Phase 4
38 Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis Recruiting NCT02770040 Phase 4
39 Two Therapeutic Strategies for the Maintenance of Remission in Patients With Ulcerative Colitis Recruiting NCT03151525 Phase 4
40 Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis Recruiting NCT03029143 Phase 4
41 Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease Recruiting NCT02743806 Phase 4
42 Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease Recruiting NCT02559713 Phase 4
43 Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis Recruiting NCT01941589 Phase 4
44 An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis Recruiting NCT02646657 Phase 4
45 Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis Recruiting NCT03110198 Phase 4
46 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Recruiting NCT02998112 Phase 4
47 Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study Recruiting NCT02760615 Phase 4
48 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Recruiting NCT01804166 Phase 4
49 Phase 4 Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis Recruiting NCT02790138 Phase 4
50 Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis Recruiting NCT02579733 Phase 4

Search NIH Clinical Center for Ulcerative Colitis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Ulcerative Colitis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Ulcerative Colitis:
MultiStem
Regenerative ColoTherapy
Embryonic/Adult Cultured Cells Related to Ulcerative Colitis:
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 21175285
Adipose-derived mesenchymal stem cells (family)
Peripheral blood-derived hematopoietic stem cells (family)

Cochrane evidence based reviews: colitis, ulcerative

Genetic Tests for Ulcerative Colitis

Anatomical Context for Ulcerative Colitis

MalaCards organs/tissues related to Ulcerative Colitis:

39
Colon, Testes, Liver, Neutrophil, T Cells, Skin, Kidney

The Foundational Model of Anatomy Ontology organs/tissues related to Ulcerative Colitis:

18
Colon
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Ulcerative Colitis:
id Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Ulcerative Colitis

Articles related to Ulcerative Colitis:

(show top 50) (show all 2406)
id Title Authors Year
1
Traditional Chinese medicine combination therapy for patients with steroid-dependent ulcerative colitis: study protocol for a randomized controlled trial. ( 28069051 )
2017
2
Squamous cell dysplasia in the proximal rectum of three patients treated for ulcerative colitis on immunomodulators. ( 28091842 )
2017
3
Mucosal Healing in Ulcerative Colitis: A Comprehensive Review. ( 28078646 )
2017
4
Effect of threatening life experiences and adverse family relations in ulcerative colitis: analysis using structural equation modeling and comparison with Crohn's disease. ( 28059861 )
2017
5
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age. ( 28070861 )
2017
6
Review article: dose optimisation of infliximab for acute severe ulcerative colitis. ( 28074618 )
2017
7
Etiopathogenesis of Nephrolithiasis in Ulcerative Colitis Patients with the Ileal Pouch Anal Anastomosis. ( 28301430 )
2017
8
Granulocyte-Monocyte Apheresis as an Adjuvant Therapy to Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis. ( 28078747 )
2017
9
Functional variant in the promoter region of IL-27 alters gene transcription and confers a risk for ulcerative colitis in northern Chinese Han. ( 28069403 )
2017
10
Gastrointestinal diseases and their oro-dental manifestations: Part 2: Ulcerative colitis. ( 28084352 )
2017
11
Surveillance for Dysplasia in Patients with Ulcerative Colitis: Discrepancy between Guidelines and Practice. ( 28066941 )
2017
12
Proteinase 3-antineutrophil cytoplasmic antibody-positive ulcerative colitis presenting with abducens neuropathy. ( 28069788 )
2017
13
Unsuspected Active Ulcerative Colitis in a Patient With Dermatomyositis: A Rare Association Detected on (18)F-FDG PET/CT During the Search for an Occult Malignancy. ( 28533643 )
2017
14
Tripeptide K(D)PT Is Well Tolerated in Mild-to-moderate Ulcerative Colitis: Results from a Randomized Multicenter Study. ( 28092306 )
2017
15
Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis. ( 28076386 )
2017
16
The Ileitis of Ulcerative Colitis. Why Is It Not Crohn's Disease? ( 28079623 )
2017
17
Exacerbation caused by 5-ASA intolerance in children with ulcerative colitis. ( 28063246 )
2017
18
Long-term Extent Change of Pediatric-Onset Ulcerative Colitis. ( 28067753 )
2017
19
Activation of NLRP3 Inflammasome in Inflammatory Bowel Disease: Differences Between Crohn's Disease and Ulcerative Colitis. ( 28523573 )
2017
20
Insights into the pathophysiology of ulcerative colitis: interleukin-13 modulates STAT6 and p38 MAPK activity in the colon epithelial sodium channel. ( 28083943 )
2017
21
Crohn's Disease and Ulcerative Colitis Show Unique Cytokine Profiles. ( 28533995 )
2017
22
Pouchitis after ileal pouch-anal anastomosis in ulcerative colitis: Diagnosis, management, risk factors, and incidence. ( 27681447 )
2017
23
An Unusual Case of Intestinal Obstruction in Ulcerative Colitis. ( 27810371 )
2016
24
Spinal epidural abscess: a rare complication of ulcerative colitis after ileal pouch anal anastomosis. ( 27822874 )
2016
25
A galectin-specific signature in the gut delineates Crohn's disease and ulcerative colitis from other human inflammatory intestinal disorders. ( 26891020 )
2016
26
Ulcerative Colitis in Colonic Interposition for Esophageal Atresia. ( 27847835 )
2016
27
Herpes simplex induced necrotizing tonsillitis in an immunocompromised patient with ulcerative colitis. ( 26881193 )
2016
28
Reversal of Refractory Ulcerative Colitis and Severe Chronic Fatigue Syndrome Symptoms Arising from Immune Disturbance in an HLA-DR/DQ Genetically Susceptible Individual with Multiple Biotoxin Exposures. ( 27165859 )
2016
29
[Interaction of MIF gene -173G/C polymorphism and GPX1 gene 594C/T polymorphism with high-fat diet in ulcerative colitis]. ( 26829742 )
2016
30
Targeting cytomegalovirus during ulcerative colitis flare-ups. ( 27211020 )
2016
31
Normalization of mucosal tumor necrosis factor-I+: A new criterion for discontinuing infliximab therapy in ulcerative colitis. ( 26775117 )
2016
32
Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis. ( 27799888 )
2016
33
Tumour necrosis factor-alpha (-308G/A) promoter polymorphism is associated with ulcerative colitis in Brazilian patients. ( 27528546 )
2016
34
Composition and function of the pediatric colonic mucosal microbiome in untreated patients with ulcerative colitis. ( 27217061 )
2016
35
[THE INFLUENCE OF TUMOR NECROSIS FACTOR ALPHA AND POLYMORPHISM OF ITS GENE (RS1800629) ON THE SEVERITY AND PROGRESSION OF CHRONIC HEPATITIS AND ULCERATIVE COLITIS]. ( 27301136 )
2016
36
Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma in a patient treated with azathioprine for ulcerative colitis. ( 27311871 )
2016
37
Male-specific association between MT-ND4 11719 A/G polymorphism and ulcerative colitis: a mitochondria-wide genetic association study. ( 27716073 )
2016
38
Once daily versus multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis. ( 27214762 )
2016
39
Prostaglandin E-major Urinary Metabolite as a Biomarker for Pediatric Ulcerative Colitis Activity. ( 27906804 )
2016
40
Effect of Long Noncoding RNA H19 Overexpression on Intestinal Barrier Function and Its Potential Role in the Pathogenesis of Ulcerative Colitis. ( 27661667 )
2016
41
Yellow fever vaccination during treatment with infliximab in a patient with ulcerative colitis: A case report. ( 27612222 )
2016
42
Restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: A narrative review. ( 27648159 )
2016
43
Lewis-Sumner syndrome associated with infliximab therapy in ulcerative colitis. ( 26838522 )
2016
44
Immunohistochemical Studies on Galectin Expression in Colectomised Patients with Ulcerative Colitis. ( 26885508 )
2016
45
Genetics and Therapeutics in Pediatric Ulcerative Colitis: the Past, Present and Future. ( 26973787 )
2016
46
Follicular lymphoma-related colitis resembling ulcerative colitis. ( 28013449 )
2016
47
A double conundrum: concurrent presentation of Hashimoto's thyroiditis and ulcerative colitis. ( 27107058 )
2016
48
Polymyositis in a patient with ulcerative colitis. ( 27032754 )
2016
49
Association of Ulcerative Colitis with FUT2 and FUT3 Polymorphisms in Patients from Southeast China. ( 26766790 )
2016
50
Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. ( 27218676 )
2016

Variations for Ulcerative Colitis

Expression for Ulcerative Colitis

LifeMap Discovery
Genes differentially expressed in tissues of Ulcerative Colitis patients vs. healthy controls: 35 (show all 12)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CLDN8 claudin 8 Colon - 4.72 0.000
2 LCN2 lipocalin 2 Colon + 4.60 0.000
3 REG3A regenerating islet-derived 3 alpha Colon + 4.41 0.001
4 SLC26A2 solute carrier family 26 (anion exchanger), member 2 Colon - 4.19 0.000
5 PCK1 phosphoenolpyruvate carboxykinase 1 (soluble) Colon - 4.13 0.000
6 CXCL8 chemokine (C-X-C motif) ligand 8 Colon + 3.86 0.003
7 CXCL2 chemokine (C-X-C motif) ligand 2 Colon + 3.85 0.000
8 REG1A regenerating islet-derived 1 alpha Colon + 3.68 0.005
9 RGS3 regulator of G-protein signaling 3 Colon + 3.58 0.000
10 CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) Colon + 3.55 0.000
11 OLFM4 olfactomedin 4 Colon + 3.25 0.014
12 DEFA6 defensin, alpha 6, Paneth cell-specific Colon + 3.22 0.003
Search GEO for disease gene expression data for Ulcerative Colitis.

Pathways for Ulcerative Colitis

Pathways related to Ulcerative Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.1 CRP CXCL8 IFNG IL10 IL1B IL2
2
Show member pathways
13.74 CXCL8 IFNG IL10 IL1B IL2 IL23R
3
Show member pathways
13.49 CXCL8 IL10 IL1B IL2 IL23R IL6
4
Show member pathways
13.47 CXCL8 IFNG IL10 IL1B IL2 IL23R
5
Show member pathways
13.4 CXCL8 IL10 IL1B IL2 IL23R IL6
6
Show member pathways
13.11 CXCL8 IL1B IL6 MUC2 NOD2 REL
7
Show member pathways
13.03 CXCL8 IFNG IL10 IL1B IL2 IL6
8
Show member pathways
12.97 CXCL8 IFNG IL10 IL1B IL2 IL6
9
Show member pathways
12.92 CXCL8 IFNG IL1B IL2 IL6 TLR4
10
Show member pathways
12.85 CXCL8 IFNG IL1B IL6 REL S100A12
11
Show member pathways
12.81 IL1B IL2 IL6 REL TLR4 TNF
12
Show member pathways
12.7 IFNG IL10 IL2 REL TNF
13 12.67 IFNG IL10 IL1B IL2 MPO REL
14
Show member pathways
12.6 IFNG IL10 IL1B IL2 IL23R IL6
15
Show member pathways
12.57 IFNG IL10 IL1B IL2 IL6 REL
16
Show member pathways
12.55 IFNG IL10 IL1B IL2 IL23R IL6
17
Show member pathways
12.47 CXCL8 IFNG IL1B IL6 REL TNF
18
Show member pathways
12.45 CRP IFNG IL1B IL2 IL6 MPO
19
Show member pathways
12.4 CXCL8 IFNG IL1B IL6 TLR4 TNF
20
Show member pathways
12.39 CXCL8 IL6 REL TLR4 TNF
21
Show member pathways
12.38 IFNG IL10 IL1B TLR4 TNF
22
Show member pathways
12.34 IFNG IL10 IL2 IL23R IL6
23 12.33 IFNG IL10 IL1B IL6 NOD2 TLR4
24 12.3 CXCL8 IL6 MPO REL
25 12.3 CXCL8 IL10 IL1B IL6 TNF
26
Show member pathways
12.29 CXCL8 IFNG IL1B IL6 REL TLR4
27 12.26 IFNG IL6 TLR4 TNF
28
Show member pathways
12.21 CXCL8 IFNG IL10 IL1B IL2 IL6
29 12.14 IFNG IL10 IL2 IL6 MPO TNF
30 12.12 CXCL8 IL10 IL1B IL23R IL6 TNF
31
Show member pathways
12.08 IFNG IL1B IL2 REL
32
Show member pathways
12.07 IFNG IL1B IL23R IL6 TLR4
33 12.06 IL1B IL6 NOD2 TNF
34 12.06 CXCL8 IFNG IL1B IL2 IL6 TLR4
35 12.05 CXCL8 IFNG IL1B IL6
36 12.02 CXCL8 IL1B IL6 TNF
37
Show member pathways
12.01 CXCL8 IL23R IL6 REL TLR4
38 12 CXCL8 IL1B TLR4 TNF
39 12 CXCL8 IFNG IL1B IL6 TLR4 TNF
40 11.97 CXCL8 IFNG IL1B IL6 TLR4
41 11.93 CXCL8 IFNG IL2 IL6
42
Show member pathways
11.9 CXCL8 IFNG IL2 TNF
43 11.89 IFNG IL10 IL1B IL2 IL23R TNF
44 11.85 IL10 IL6 TLR4 TNF
45 11.85 IFNG IL10 IL1B IL2 IL6 TNF
46 11.84 CXCL8 IL10 IL1B IL6 TLR4 TNF
47 11.83 IFNG IL10 IL2 IL6
48 11.8 CXCL8 IL1B IL6 TNF
49
Show member pathways
11.79 IFNG IL10 IL1B IL2 IL23R IL6
50 11.75 CXCL8 IL1B IL6 TLR4 TNF

GO Terms for Ulcerative Colitis

Cellular components related to Ulcerative Colitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 CRP CXCL8 IFNG IL10 IL1B IL2
2 extracellular region GO:0005576 9.4 CRP CXCL8 IFNG IL10 IL1B IL2

Biological processes related to Ulcerative Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 73)
id Name GO ID Score Top Affiliating Genes
1 defense response GO:0006952 9.99 CXCL8 MPO NOD2 TNF
2 activation of MAPK activity GO:0000187 9.97 IL1B NOD2 TLR4 TNF
3 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.97 IL10 IL1B IL6 TNF
4 response to glucocorticoid GO:0051384 9.94 IL10 IL6 TNF UCN
5 positive regulation of JNK cascade GO:0046330 9.92 IL1B NOD2 TLR4 TNF
6 neutrophil chemotaxis GO:0030593 9.92 CXCL8 IFNG IL1B S100A12
7 cellular response to organic cyclic compound GO:0071407 9.91 IL1B NOD2 TNF
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.91 IL6 TNF UCN
9 defense response to Gram-positive bacterium GO:0050830 9.91 CRP IL6 TNF
10 regulation of insulin secretion GO:0050796 9.91 IFNG IL1B TNF
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.91 IL1B IL6 NOD2 S100A12 TLR4 TNF
12 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.9 REL TLR4 TNF
13 positive regulation of inflammatory response GO:0050729 9.89 IL2 S100A12 TLR4
14 humoral immune response GO:0006959 9.89 IFNG IL6 TNF
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 IFNG IL2 IL23R IL6
16 defense response to Gram-negative bacterium GO:0050829 9.88 IL23R IL6 TLR4
17 negative regulation of neuron death GO:1901215 9.87 IL6 REL UCN
18 positive regulation of tumor necrosis factor production GO:0032760 9.87 IFNG NOD2 TLR4
19 lipopolysaccharide-mediated signaling pathway GO:0031663 9.85 IL1B TLR4 TNF
20 positive regulation of T cell proliferation GO:0042102 9.85 IFNG IL1B IL2 IL23R IL6
21 cellular response to lipopolysaccharide GO:0071222 9.85 CXCL8 IFNG IL10 IL6 TLR4 TNF
22 negative regulation of interleukin-6 production GO:0032715 9.84 IL10 TLR4 TNF
23 positive regulation of interleukin-8 production GO:0032757 9.84 IL1B NOD2 TLR4 TNF
24 positive regulation of interleukin-12 production GO:0032735 9.83 IFNG IL23R TLR4
25 positive regulation of NF-kappaB import into nucleus GO:0042346 9.83 IL1B TLR4 TNF
26 positive regulation of osteoclast differentiation GO:0045672 9.82 IFNG IL23R TNF
27 defense response to protozoan GO:0042832 9.82 IFNG IL10 IL6
28 positive regulation of chemokine production GO:0032722 9.81 IL6 TLR4 TNF
29 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.8 IFNG IL1B TNF
30 defense response to bacterium GO:0042742 9.8 IFNG IL10 MPO NOD2 S100A12 TLR4
31 positive regulation of interleukin-17 production GO:0032740 9.79 IL2 IL23R NOD2
32 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.77 IL10 IL1B TNF
33 positive regulation of chemokine biosynthetic process GO:0045080 9.76 IFNG IL1B TNF
34 maintenance of gastrointestinal epithelium GO:0030277 9.75 MUC2 NOD2
35 positive regulation of immunoglobulin secretion GO:0051024 9.75 IL2 IL6
36 negative regulation of lipid storage GO:0010888 9.75 CRP IL6 TNF
37 positive regulation of protein import into nucleus, translocation GO:0033160 9.74 IFNG IL6
38 response to auditory stimulus GO:0010996 9.74 IL6 UCN
39 negative regulation of hormone secretion GO:0046888 9.74 IL6 UCN
40 negative regulation of interleukin-17 production GO:0032700 9.74 IFNG TLR4
41 positive regulation of isotype switching to IgG isotypes GO:0048304 9.74 IFNG IL2
42 positive regulation of MHC class II biosynthetic process GO:0045348 9.74 IFNG IL10 TLR4
43 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.73 IL1B IL23R
44 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.73 IFNG IL1B
45 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.73 TLR4 TNF
46 endothelial cell apoptotic process GO:0072577 9.72 IL10 TNF
47 regulation of defense response to